Print This Page
Email to a Friend

Important Safety Information Full Prescribing Information

      
  • Aloxi Home
  • PONV Patients and Caregivers
  • CINV Patients and Caregivers
    • About ALOXI
      • How does ALOXI work?
      • For discussion with your healthcare professional
      • Ingredients and administration
      • Important Safety Information
    • Understanding CINV
      • Types of CINV
      • Prevent CINV
      • What are the most distressing side effects
      • Perception vs Reality
    • Tips to Prevent CINV
    • Online resources
    • ALOXI Patient Support Program
  • Healthcare professionals
    • About Aloxi®
      • Binding Affinity
      • Indication
      • Safety Profile
      • Multi-Day Dosing
    • ALOXI® Phase III Clinical Trials
      • ALOXI® vs. Ondansetron in Moderately Emetogenic Chemotherapy
      • ALOXI® vs. Dolasetron in Moderately Emetogenic Chemotherapy
      • ALOXI® vs. Ondansetron in Highly Emetogenic Chemotherapy
    • Nausea & Vomiting
      • Perception vs Reality
      • Acute Nausea & Vomiting
      • Delayed Nausea & Vomiting
      • Anticipatory Nausea & Vomiting
      • Emetogenicity Chart
      • Impact of Failed CINV Prevention
      • Impact on the Practice
    • ALOXI® Patient Information
    • Formulary Request Letter
    • Eisai Medical Services
    • Especially for nurses
    • ALOXI® Reimbursement
Prescribing Information | Sitemap | Legal Notice and Disclaimers | Privacy

This Web site is intended for U.S. residents only.

ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.
Distributed and marketed by Eisai Inc.
© 2010 Eisai Inc.
All rights reserved. AL470A 1/10